1. Pink Sheet
  2. >>Rare Diseases

US FDA Expands Patient Input To New Area: Orphan Grant Applications

 
• By Derrick Gingery

Patient experience will be incorporated into agency orphan grant reviews, and outside rare disease experts will help make decisions.

FDAEntrance_1200x675

Outside experts will help the US FDA's Office of Orphan Products Development review grant applications and patient views will be given to the grant review staff to incorporate into decisions. Both should offer the rare disease community more power over trial designs and FDA's orphan drug research agenda.

OOPD Director Janet Maynard and FDA Patient Affairs Staff Director Andrea Furia-Helms said in a Feb. 28 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Pink Sheet

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.